Safety (AE, adverse drug reaction): anemia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF
Ruxolitinib showed no clear difference in safety (AE, adverse drug reaction): anemia Grades 3 or 4 according… compared with best available therapy (low certainty).
1 finding from 1 review
Bleeding: Number of days on which a significant bleeding event occurred3 · People with a haematological disorder
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
Intervention not reported
Overall survival ( · people with relapsed or refractory DLBCL
1 finding from 1 review
Intervention not reported
Quality of life ( · people with relapsed or refractory DLBCL
1 finding from 1 review
Intervention not reported
Any adverse events ( · people with relapsed or refractory DLBCL
1 finding from 1 review
Intervention not reported
Any serious adverse events ( · people with relapsed or refractory DLBCL
1 finding from 1 review
Intervention not reported
Cytokine release syndrome ( · people with relapsed or refractory DLBCL
1 finding from 1 review
Intervention not reported
Progression‐free survival ( · people with relapsed or refractory DLBCL
1 finding from 1 review
Intervention not reported
Complete response ( · people with relapsed or refractory DLBCL
1 finding from 1 review
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with vitamin K antagonist (VKA) (very low certainty).
2 findings from 1 review
Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes symptomatic deep vein thrombosis compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes pulmonary embolism compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes major bleeding compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes minor bleeding compared with low molecular weight heparin (LMWH) (very low certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes symptomatic deep vein thrombosis compared with vitamin K antagonist (VKA) (very low certainty).
2 findings from 1 review
Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review